Latest Ai Platforms News

dorsaVi reports breakthrough RRAM sensor performance and secures a major US physical therapy deal, backed by a $5 million capital raise and new leadership appointments.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Janison Education Group reported solid FY25 results with 9% revenue growth and the commercial launch of its AI platform Jai, positioning itself strongly in the expanding global digital assessment market.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Vection Technologies has secured $1.5 million in AI-driven enterprise orders spanning agritech, cybersecurity, real estate, healthcare, and public administration, reinforcing its recurring revenue model and cross-sector appeal.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

SenSen Networks reported a record first quarter for FY26 with $4.3 million in cash receipts and positive operating cashflow, driven by new contracts across Singapore, the USA, and Australia. The company’s AI platform SenDISA continues to expand its footprint in Smart City solutions.

Hiremii Group has successfully raised $650,000 through an oversubscribed placement, underscoring strong investor confidence as it pushes forward with commercialising its AI-driven recruitment platform.

Horizon Gold reports significant gold intercepts from water bore drilling at its Gum Creek Project and launches an AI-powered exploration partnership to accelerate resource growth.

Artrya Limited has successfully completed a strongly supported Share Purchase Plan, raising approximately A$5 million despite significant oversubscription. This follows a recent $75 million placement, underscoring investor confidence in its AI-driven coronary artery disease platform.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.